Clinical management of tuberculosis in the context of HIV infection

被引:66
作者
de Jong, BC [1 ]
Israelski, DM
Corbett, EL
Small, PM
机构
[1] Stanford Univ, Div Infec Dis & Geog Med, Stanford, CA 94305 USA
[2] Bill & Melinda Gates Fdn, Seattle, WA 98102 USA
[3] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England
[4] San Mateo Med Ctr, Div Infect Dis, San Mateo, CA 94403 USA
来源
ANNUAL REVIEW OF MEDICINE | 2004年 / 55卷
关键词
treatment; drug interactions; immune reconstitution syndrome;
D O I
10.1146/annurev.med.55.091902.103753
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Globally, the HIV and tuberculosis epidemics are stoking each other, creating a public health crisis of enormous proportions. At the level of individuals, contemporaneous infection with M. tuberculosis and HIV poses great challenges to clinical management. This chapter provides an overview of active and latent tuberculosis treatment in HIV-infected and -uninfected individuals. The discussion focuses on medication issues, including interactions between antitubercular drugs, antiretroviral drugs, and medicines used for opportunistic infections and treatment in the face of comorbidities. Clinical questions specific to coinfection are discussed, including duration and timing initiation of therapy and immune reconstitution. Most of the data presented were generated in industrialized settings and are presented to assist patient management in such settings. However, given the disproportionate amount of TB/HIV in less-developed nations and the increasing availability of antiretroviral therapy in resource-limited settings, the issues presented will become increasingly relevant globally.
引用
收藏
页码:283 / 301
页数:19
相关论文
共 80 条
  • [1] RESPONSE TO TREATMENT, MORTALITY, AND CD4 LYMPHOCYTE COUNTS IN HIV-INFECTED PERSONS WITH TUBERCULOSIS IN ABIDJAN, COTE-DIVOIRE
    ACKAH, AN
    COULIBALY, D
    DIGBEU, H
    DIALLO, K
    VETTER, KM
    COULIBALY, IM
    GREENBERG, AE
    DECOCK, KM
    [J]. LANCET, 1995, 345 (8950): : 607 - 610
  • [2] Andrade Adriana, 2003, Hopkins HIV Rep, V15, P11
  • [3] [Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
  • [4] [Anonymous], 1998, MMWR Recomm Rep, V47, P1
  • [5] [Anonymous], 2000, MMWR Recomm Rep, V49, P1
  • [6] Apseloff G, 1998, J CLIN PHARMACOL, V38, P830
  • [7] Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study
    Badri, M
    Wilson, D
    Wood, R
    [J]. LANCET, 2002, 359 (9323) : 2059 - 2064
  • [8] Tuberculosis in patients with HIV infection
    Barnes, PF
    Lakey, DL
    Burman, WJ
    [J]. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2002, 16 (01) : 107 - +
  • [9] Drug treatment for tuberculosis during pregnancy - Safety considerations
    Bothamley, G
    [J]. DRUG SAFETY, 2001, 24 (07) : 553 - 565
  • [10] Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals
    Breen, RAM
    Lipman, MCI
    Johnson, MA
    [J]. AIDS, 2000, 14 (05) : 615 - 615